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Aims 
In a high proportion of people with recently diagnosed Type 2 diabetes, a short (2 to 3 month) 
low calorie diet is able to restore normal glucose and insulin metabolism. The aim of this study 
is to determine the feasibility of this approach in Barbados.  
Methods 
Twenty-five individuals, aged 20 to 69 years, Type 2 diabetes diagnosed within past 6 years, 
not on insulin, BMI > 27 Kgm-2 were recruited. Hypoglycaemic medication was stopped on 
commencement of the 8-week liquid (760 calorie) diet, during which participants were 
assessed weekly and then monthly to 8 months. Insulin response was assessed in meal tests 
at baseline, 8 weeks and 8 months.  ‘Responders’ were those with FPG < 7mmoll-1 at 8 weeks.  
Results 
10 men and 15 women (mean age 48, range 26-68yrs) participated. Mean (SD) BMI was 34.2 
Kgm-2 (6.0), FPG 9.2 mmoll-1(2.2). Mean weight loss at 8 weeks and 8 months was 10.1Kg (95% 
CIs 8.1, 12.0) and 8.2 Kg (5.8,10.6); FPG was lower by 2.2mmoll-1 (1.2, 3.2) and 1.7mmoll-1 (0.8, 
2.7) respectively. There were 15 ‘responders’, 9 of whom lost >10kg compared to 2 (20%) 
non-responders (p=0.048). 30 minute insulin increment was significantly higher in responders 
at baseline and follow up, as was total insulin secretion (Phitot) at 8 months (ps=0.01).   
Conclusions 
The feasibility of this approach to weight loss and diabetes remission in a predominantly black 
population in Barbados was demonstrated. Remission at 8 weeks was associated with a 
greater baseline insulin response and initial weight loss.  
 
  
 
 
  
Introduction 
 
The Caribbean population, predominantly of African origin, has overall rates of diabetes 
amongst the highest in the world[1, 2]. Underlying these high rates of T2DM are high levels 
of overweight and obesity, affecting over half of all women and men[3]. In Barbados the 
prevalence of diabetes in adults aged 25 years and over was 18.7% (21.0% in women, 15.9% 
in men) in 2012; with an obesity prevalence of 33.8% (43.4 women; 23.4 men)[4]. This is 
associated with high rates of diabetes related complications, with Barbados having been 
labelled in the past as the ‘amputation capital of the world’[5].  
 
Although T2DM has long been regarded as a lifelong, steadily progressive disease[6, 7] 
recent understanding of the aetiology of the condition changes this. It is caused by excess 
accumulation of fat in liver and pancreas in susceptible individuals, causing failure of control 
of hepatic glucose production in the liver and loss of insulin secretory capacity in the 
pancreas[8-10] . The former remains completely reversible, and the latter is reversible in a 
high proportion of people during the first 6 years after diagnosis.  In the weight 
management for remission of type 2 diabetes trial (DiRECT), remission of type 2 diabetes 
was achieved in 46% in the intervention group (compared to 4% in the control group). 
Weight loss was achieved through a low calorie liquid diet, and remission success rates were 
associated with the degree of weight loss, being over 80% in those who lost more than 15Kg 
at 12 months [11].   
 
The DiRECT study was conducted in the North of England and Scotland and less than 2% of 
participants were of non-white ethnicity[11], and this was also the case in the earlier proof 
of concept work[9, 12]. Successful application of this approach in populations and countries 
with different cultures and food systems cannot be assumed. In addition, neither should it 
be assumed that the underlying physiology and metabolic responses to weight loss are the 
same in ethnically distinct populations[13]. The aim of the present study was to examine in 
people with type 2 diabetes in Barbados the feasibility and metabolic outcomes of the 
approach used in the UK to bringing about the remission of type 2 diabetes.  
 
Methods 
The overall design of this eight month feasibility study followed closely that of similar work 
conducted in the UK[9, 12], and is summarised in figure 1.  The study received ethical 
approval from the University of the West Indies Institutional Review Board, and from the 
Ministry of Health of the Government of Barbados. 
 
Study participants 
Twenty-five participants with type 2 diabetes were recruited through a combination of 
publicity and contacts with local government and private health care providers. Participants 
had to be residents of Barbados with the following characteristics: 
● Aged 20 – 69 years 
● Diagnosed with type 2 diabetes (based on World Health Organization criteria) for 6 
years or less 
● Body Mass index (BMI) of > 27 kg/m2  
 
Criteria excluding participation in the study were: current insulin use, HbA1c > 12%, substance 
abuse, known cancer, myocardial infarction within the past 6 months, learning difficulties, 
current treatment with anti-obesity drugs, diagnosed eating disorder or purging, 
pregnant/considering pregnancy, evidence of liver disease (including liver enzymes > 3 times 
above normal values) or renal disease (creatinine of > 150 mmol/l) and persons who have 
required hospitalisation for depression, or are on antipsychotic drugs.   
 
The intervention 
The intervention was delivered by a family practitioner (KB), following a detailed study 
protocol that included how to provide support to participants to address challenges in 
adhering to the dietary guidance.  Participants were encouraged to phone KB between visits 
should they need advice. 
 
Participants stopped any glucose lowering medication on the day of starting the liquid diet 
(at time 0). The liquid diet was given at no cost to participants and consisted of 4 shakes per 
day, each shake containing 190 calories, and made up of 23g of carbohydrate, 10g of protein 
and 7g of fat. Participants were encouraged to drink 3 litres of water a day, and to consume 
3 to 4 portions of high fibre low carbohydrate vegetables per day. They were provided with a 
specially prepared recipe book for local low carbohydrate vegetables. After 8 weeks on the 
liquid diet they transitioned over a 4-week period back to a solid diet, with support and 
guidance from a local dietician on eating healthily and on taking regular exercise.  Remission 
of diabetes was defined as achieving a fasting plasma glucose of less than 7.0mmol/l as 
previously reported [12, 14]. 
 
Data collection 
As shown in the figure 1, participants were seen weekly during the liquid diet phase, and 
monthly thereafter. At each visit, weight, waist circumference, blood pressure and fasting 
glucose were measured following standard protocols. Height was measured at the first visit. 
Weight was measured on a Seca 813 digital scale, waist and hip circumferences were 
measured twice, with a third measurement being taken if they differed by more than 0.5 cm, 
and the mean of the two closest measurements used in analysis. Blood pressure was taken 
after the participant had been seated for at least 15 minutes. It was measured three times in 
the right arm using an Omron 705 CP digital monitor and an appropriate size cuff. The mean 
of the second and third measurements were used in analysis. Fasting glucose was measured 
on capillary blood using a Hemocue 201 RT analyser, with results given in plasma equivalent 
values.     
 
Participants underwent three standard meal tests, each consisting of 2 Weetabix, 200ml 
semi-skimmed milk, 200ml orange juice, a white bread roll, 20g of strawberry jam, and 10g of 
margarine (equating to 575 calories, 72% carbohydrate, 15% protein, 13% fat). Blood samples 
were taken when the participant was fasting and then at 10, 20, 30, 60, 90 and 120 minutes 
after the meal. At each time point blood was taken for the measurement of glucose, and 
serum was stored at minus 80 degrees for the subsequent measurement of c-peptide, insulin, 
and non-esterified fatty acids (NEFA). In addition, on the fasting sample were measured: 
HbA1c (Bayer DCA 2000 analyser); total, HDL cholesterol, triglycerides, calculated LDL 
cholesterol and ALT (Roche Reflotron plus).  
 
Modelling insulin response 
Beta cell insulin secretion was calculated from the oral C-peptide minimal model [15].  
Modelling of insulin secretion was possible in 7/15 responders and 5/10 non-responders at 
baseline; 10/15 and 7/10 respectively at 8 weeks; and 13/15 and 7/10 respectively at 8 
months. 
 
Sample size and statistical analysis  
The sample size of 25 was chosen for this feasibility study based on the experience of the 
study in Newcastle, UK[9], which demonstrated highly significant changes with a sample size 
of 11. It was estimated that 25, even allowing for some attrition, would provide more than 
adequate power for meaningful before and after analyses. For example, with 20 participants 
it would be possible to demonstrate a 4Kg weight difference before vs after, at p<0.05 and 
with 90% power. In the Newcastle study the mean weight loss was 15 Kg. For fasting glucose, 
20 participants would enable a difference 1.1 mmol/l to be detected. Similar considerations 
apply to other measures, including waist circumference, and fasting insulin.   
  
Data were analysed using STATA statistical software.   Descriptive statistics for the group as 
a whole are presented as means (SD) or medians (IQR) as appropriate. Differences between 
groups and overtime (e.g. between baseline and follow up) are presented with 95% 
confidence intervals. Exploratory analyses were undertaken to compare the characteristics 
of ‘responders’ (fasting glucose, off medication, < 7 mmol/l by the end of 8 week liquid diet 
phase) to ‘non-responders’.   
 
Results 
 
Baseline clinical and metabolic characteristics 
 
Mean BMI was 34.2 (SD 6.0), age 48 (10) years, 60% were female and 88% classified 
themselves as black ethnicity, 8% as mixed, 4% as white. All males and 80% of females were 
taking oral hypoglycaemic agents. The duration of diagnosed diabetes reflected the 
selection criteria, being 3.0 (2.1) years. 60% of the men and 40% of the women were taking 
antihypertensive therapy. Full details are shown in Table 1.  
 
Fasting plasma glucose and HbA1c were 9.2 (2.2) mmol/l and 8.1% (1.7%) respectively, and 
similar in men and women. 40% of men and 13% of women were taking a statin, and mean 
total and LDL cholesterol levels were below 5 and 3 mmol/l respectively in both men and 
women. Mean plasma ALT was within the normal range and was higher in men than women 
(difference 10.8, 95% CIs 2.0, 19.6)(Table 1).  
 
Effect of intervention on weight and metabolic parameters 
 
As shown in table 2, during the 8-week low calorie diet phase mean weight fell by 10.1Kg 
(95% CIs on the decrease: 8.1, 12.0). The range of weight loss was 1.5 to 20.8kg. 11/25 
people lost more than 10Kg and 4/25 more than 15Kg. Mean BMI fell by 3.4 Kg/m2 (2.9, 4.0), 
and mean waist circumference by 10.9 cm (9.3, 12.5). Between the end of the low-calorie 
diet and month 8, mean weight increased by 1.8Kg (-0.3, 3.9), p=0.09), although this 
increase was not statistically significant (p=0.09).  
 
Following withdrawal of all hypoglycaemic agents and commencement of the low-calorie 
diet, fasting plasma glucose decreased by a mean of 1.5 mmol/l (0.5, 2.5) by week 2, 2.0 
mmol/l (1.1, 3.0) by week 3, and 2.2 mmol/l (1.2, 3.3) by week 8. Thus, mean fasting glucose 
at week 8 was 7.0 mmol/l (SD 1.4). At week 8, 60% (15/25) of the group achieved FPG 
<7mmol/l, and of those who lost more than 10kg 82% (9/11) achieved FPG <7.0mmol/l. 
Between week 8 and the end of follow up mean fasting glucose increased by 0.6 mmol/l (-
0.04, 1.15, p=0.07). Six months after the end of the low-calorie diet phase, 9 of 24 (37.5%) 
who were followed up had a FPG < 7.0 mmol/l. 
 
Mean HbA1c fell significantly between baseline and week 8 by 0.9% (0.3, 1.4).  It increased 
between week 8 and the end of the follow up by 0.2% (-0.6, 1.0).  Thus, by the end of follow 
up the mean fall in HbA1c compared to baseline was 0.7% (-0.3, 1.6, p=0.19).  
 
There was evidence of improvement in both triglycerides and HDL cholesterol levels. 
Compared to baseline, triglycerides showed a significant decrease at week 8, (0.23 mmol/l, 
95% CIs 0.05, 0.41), and HDL cholesterol a significant increase at the end of the follow up 
period (0.17mmol/l, 0.01, 0.32). Fasting plasma NEFA did not change from baseline to 8 
weeks (1.040.14 and 1.170.18mmol/l) but fell to 0.680.12 mmol/l (p<0.01 compared 
with baseline) by 8 months. The post-meal suppression of plasma NEFA did not change 
during the study (0.560.13, 0.730.13, and 0.470.23 mmol/l respectively).  
  
Characteristics in responders vs non-responders 
 
Selected baseline characteristics of responders and non-responders are compared in table 
3.  Responders and non-responders had a similar age and duration of diabetes. A higher 
proportion of men were responders (8/10) than women (7/15), giving a relative risk of 1.7 in 
favour men but with confidence intervals compatible with a larger or no sex difference (0.9 
to 3.2).  Mean baseline weight was 6.2Kg higher in responders, but confidence intervals are 
wide (-11.4 to 23.8). Baseline fasting glucose and HbA1c were similar.  
 
Absolute and percentage mean weight loss was slightly higher in responders vs non-
responders, being 10.7Kg vs 9.2 Kg and 10.1% vs 9.4 % respectively, but confidence intervals 
on these differences cross zero (table 3).  81.8% of those who lost 10Kg or more responded 
compared 42.9% who lost less than 10Kg, risk ratio 1.9 (95% CI 1.0 to 3.7, p=0.048).  
 
In responders, between baseline and week 8, fasting glucose fell by 3.2 mmol/l (95% CIs 2.4, 
4.5), compared to 0.8 mmol/l (-0.5, 2.1) in non-responders. There was no significant change 
in fasting insulin in either group (p> 0.2) or in ALT (p> 0.3). A marginally statistically 
significant fall was seen in triglyceride levels in the responders (0.27mmol/l, 95% CIs 0, 0.54 
p=0.053) but not in the non-responders (0.18mmol/l, -0.07, 0.42, p=0.14).  
 
There was no significant change in 0 to 30 insulin increment between baseline and week 8 in 
either responders or non-responders (p > 0.6), nor in the 0 to 30 C-peptide increment (p > 
0.1). 
Response to standard meal test 
 
For the group as a whole there was a marked improvement in meal tolerance after the 
weight loss period (Figure 2).  In addition to fasting glucose falling from 9.2 to 7.0 mmol/l 
(95% CIs on the decrease: 1.2 to 3.2) between baseline and week 8, 60 min glucose fell from 
13.3 to 10.4 mmol/l (1.5 to 4.2) and 120 min glucose from 13.5 to 10.8 mmol/l (0.9 to 4.5). 
At 8 months, fasting (7.5 (SD 0.3)), 60 min (11.0 (0.6)) and 120min (10.5 (0.7)) glucose were 
not significantly different to the 8 week values.  
 
In the responders (n=15), there was a significant increase in fasting plasma glucose 
(p=0.001), but no significant change at 60 or 120 minutes during the meal test, between 
week 8 and 8 months (fasting: +1.1mmol/l (95% CI 0.5 to 1.7), 60 minutes: +0.8mmol/l (95% 
CI -0.1 to 1.6), and 120 minutes +0.1 mmol/l 95% CI -1.4 to 1.5). In the non-responders there 
was no significant change between baseline and 8 weeks (fasting: +0.8mmol/l, 60 min: +1.6 
mmol/l and 120 minute +1.1 mmol/l). Between 8 weeks and 8 months no further change 
occurred. 
 
The 30 minute increment in plasma insulin was significantly greater at baseline in the 8 
week responder group (70.2 vs 32.0 pmol/l; diff 38.2, 95% CIs 1.4 to 75.1). This difference 
persisted at 8 weeks (75.3 vs 29.1 pmol/l; diff 46.2, 95% CIs 14.6 to 77.9) and at 8 months 
(72.4 vs 31.2 pmol/l; diff 41.2, 95% CIs 8.0 to 74.4). The 30 minute plasma C-peptide 
response was not significantly higher in responders at baseline but was significantly higher 
in the responders at 8 weeks (3.7 vs 1.5; diff 2.2, 95%CIs 0.9 to 3.5) and at 8 months (3.4 vs 
1.3; diff 2.2, 95% CIs 0.6 to 3.8).  
  
Basal  (Phib) and total beta-cell responsivity (Phitot) were numerically but not significantly 
higher in responders compared to non-responders at baseline. By 8 weeks, the greater Phib 
was significantly higher in the responders. This was maintained at 8 months, and Phitot was 
also significantly higher in the 8 week responder group (Table 4). In responders there was a 
tendency for Phib to improve between baseline and 8 weeks, and Phitot to improve up to 8 
months although these differences did not reach statistical significance. 
 
 
Conclusion  
 
This study demonstrates that non-diabetic levels of glucose control can be restored by 
dietary means in Barbadian people with type 2 diabetes. At the end of the 8 week liquid 
diet, those losing more than 10kg in weight, 81.8% (9/11) returned to non-diabetic levels of 
blood glucose control. In the whole group, 37.5% remained non-diabetic at the end of the 
study. The weight loss achieved in the whole group was substantial although less than that 
obtained by similar methods in studies elsewhere. Individuals who achieved non-diabetic 
blood glucose control were characterised at baseline by having better preserved beta cell 
function as indicated by a greater early insulin response to the standard test meal.  
The definition of remission of diabetes used in this study is consistent with previous studies 
(achieving a non-diabetic level of HbA1c or fasting plasma glucose after weight loss and off 
all hypoglycaemic agents) [16, 17]. The threshold to diagnose diabetes remains that agreed 
by the American Diabetes Association and the World Health Organisation (2002), as a 
fasting plasma glucose of 7.0mmol/l or more (or subsequently, HbA1c of 48mmol/mol 
(6.5%) or more). In clinical practice, confirmation by a second test at least two months later 
is wise [14]. It is important to recognise that following weight loss, maintenance of a non-
diabetic levels of fasting plasma glucose is associated with profound benefits in 10 year 
cardiovascular risk (QRISK 23% to 7%) [17, 18]. The state of ‘post-diabetes’ is profoundly 
different to pre-diabetes in weight, plasma lipids and blood pressure, and even though 
plasma glucose levels may be above the defined normal range it is likely that this will 
impinge little upon their long term health. Long term follow up after bariatric surgery 
demonstrates the low cardiovascular event rate consistent with the prognostic scores [19]. 
In other populations, HbA1c is usually used to define overall degree of glucose control. 
However, we have previously demonstrated that HbA1c tends to be higher in the Barbadian 
population for any given level of fasting glucose giving a substantially higher prevalence of 
type 2 diabetes than fasting glucose (ref: Unwin, Journal Global Health, 2017 – to add in). 
Accordingly, in the present study we have used fasting plasma glucose to define categories 
of glycaemic control.  
It is notable that both plasma lipids (total and LDL chol, and triglyceride) and blood pressure 
are lower than in comparable Caucasian populations with type 2 diabetes [17, 20, 21]. 
Nonetheless macrovascular disease is common, with mortality rates from ischaemic heart 
disease and stroke in Barbados exceeding those in North America ( ref?). It may be that 
susceptibility to these factors is greater for any given measured level of exposure. This 
raises questions about the aetiological basis of type 2 diabetes in the Barbadian population. 
For any given degree of adiposity, both liver and pancreas fat levels are lower in black 
populations [22]. This is reflected in the plasma ALT levels observed in the present study in 
comparison to our previous studies in largely Caucasian research groups [17, 20, 21]. Given 
the similarity of glycaemic response to weight loss, it appears likely that there are different 
levels of susceptibility to excess intra-organ triglyceride such that an increase from a lower 
baseline might be observed during the development of type 2 diabetes in Afro-Caribbean 
populations. Direct study of liver and pancreas fat content is required in future studies of 
reversing diabetes.  
 
As noted above, mean weight loss in this study (10Kg) was less than that achieved in similar 
studies in the UK (15Kg). This emphasises the importance of understanding local food 
environments and cultures, and tailoring the delivery of the weight loss interventions 
accordingly. In depth qualitative interviews were undertaken with study participants at 
baseline, 8 weeks and 8 months, with the aim of understanding the challenges from 
participants’ perspectives. These data are in the process of being written up in detail. Initial 
analyses have highlighted the difficulties of adhering to the low calorie diet when living, 
socialising and working with family, friends and colleagues whose view large plates of food 
as normal and desirable. They have also highlighted the relative lack of access to and 
expense of fresh fruits and vegetables in Barbados, and the relative lack of healthy choices 
from commercial food outlets (ref – Maddy WIMJ abstract 2016?).  
 
 
 
Summary 
Remission of Type 2 diabetes is possible in the population of Barbados. The underlying 
biology of the condition appears to be similar to that demonstrated in largely Caucasian 
populations, while acknowledging that further work to investigate the relationships 
between glucose metabolism and intrahepatic and intrapancreatic fat in this Caribbean 
population is desirable. However, perhaps the major challenge that this feasibility has 
highlighted is that of achieving greater than an average of 10kg weight loss in order to 
maximise the potential for diabetes remission.  
 
  
Table 1 – Baseline Characteristics of Study Population. Figures are means (SD)  
 
 Men (n=10) Women (n=15) All (n=25) 
    
Age (y) 51 (12) 46 (9) 48 (10) 
Ethnicity    
Black  80.0% 93.3% 88.0% 
White 0.0% 6.7% 4.0% 
Mixed 20.0% 0.0% 8.0% 
    
Diabetes treatment    
Diet only  0% 20% 12% 
Oral medication  100% 80% 88% 
Years since diagnosis (y) 3.0 (1.8) 3.1 (2.3) 3.0 (2.1) 
    
Weight (Kg) 107.7 (22.3) 92.3 (17.6) 98.5 (20.7) 
Height (cm) 177.7 (8.9) 164.0 (5.6) 169.5 (9.7) 
BMI (Kg/m2) 33.9 (5.5) 34.4 (6.6) 34.2 (6.0) 
Waist circumference (cm) 110.4 (14.7) 102.0 (15.1) 105.4 (15.2) 
    
Fasting plasma glucose (mmol/l) 9.2 (2.2) 9.3 (2.2) 9.2 (2.2) 
HbA1c (%) 8.0 (1.9) 8.2 (1.6) 8.1 (1.7) 
ALT (check units) 27.2 (14.4) 16.4 (6.7) 20.7 (11.5) 
Total Cholesterol (mmol/l) 3.7 (0.8) 4.3 (0.7) 4.0 (0.8) 
HDL Cholesterol (mmol/l) 0.77 (0.24) 0.86 (0.28) 0.82 (0.26) 
LDL Cholesterol (mmol/l) 2.4 (0.8) 2.9 (0.7) 2.7 (0.8) 
Triglycerides (mmol/l) 1.30 (0.44) 1.04 (0.41) 1.15 (0.43) 
Statin therapy 40.0% 13.3% 24.0% 
    
Systolic BP (mmHg) 134.1 (15.6) 125.5 (11.3) 129.1 (13.7) 
Diastolic BP (mmHg) 79.3 (8.0) 79.7 (7.6) 79.5 (7.6) 
On treatment for raised BP 60% 40% 48% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Change in Selected Characteristics Between Baseline and Follow-up. Data are 
mean differences (95% confidence intervals): baseline values minus those at follow up  
 
 8 weeks 5 months 8 months 
    
Weight (Kg) 10.1 (8.1, 12.0)d 9.9 (7.9, 12.0)d 8.2 (5.8, 10.6)d 
BMI (Kg/m2) 3.4 (2.9, 4.0)d 3.4 (2.8, 4.1)d 2.9 (2.1, 3.7)d 
Waist (cm) 10.9 (9.3, 12.5)d 11.1 (9.2, 12.9)d 9.8 (7.5, 12.0)d 
    
Fasting glucose (mmol/l) 2.2 (1.2, 3.2)d 2.1 (1.0, 3.2)d 1.7 (0.8, 2.7)d 
HbA1c (%)a 0.9 (0.3, 1.4)c  0.6 (-0.3, 1.6) 
    
HDL Cholesterol  (mmol/l)a -0.04 (-0.12, 0.05)  -0.17 (-0.32, -0.01)b 
Triglycerides (mmol/l)a 0.23 (0.05, 0.41)b  0.09 (-0.05, 0.22) 
    
Systolic  blood pressure (mmHg) 7.8 (-0.2, 15.7) 5.9 (-1.5, 13.2) 3.9 (-2.7, 10.6) 
Diastolic blood pressure (mmHg) 7.8 (3.2, 12.4)c 6.1 (2.6, 9.6)c 4.3 (0.2, 8.4)b 
aNot measured at 5 months; bp<0.05; cp<0.01; dp<0.001 
 
 
 
 
  
Table 3 – Comparison of baseline characteristics and weight loss in responders (FPG < 
7mmol/l at 8 weeks) and non-responders (FPG >= 7mmol/l at 8 weeks) 
 
 Responders  Non-responders 
Difference  
(95% CIs) 
p value 
Baseline Characteristics     
Age 48.3 (11.3) 47.5 (9.2) 0.8 (-8.1, 9.6) 0.86 
Male(%) 80 20   
Female(%) 46.7 53.3 1.7 (0.9, 3.2)a 0.10 
Duration Diabetes 2.9 (2.2) 3.2 (2.1) -0.3 (-2.1, 1.6) 0.76 
Weight 101.0 (23.1) 94.8 (16.7) 6.2 (-11.4, 23.8) 0.47 
BMI 35.1 (6.7) 32.8 (4.9) 2.3 (-2.8, 7.4) 0.36 
Waist  circumference 107.5 (16.4) 102.2 (13.3) 5.3 (-7.7, 18.2) 0.41 
     
FPG 9.3 (2.4) 9.1 (1.7) 0.2 (-1.6, 2.1) 0.79 
HbA1c 7.9 (1.7) 8.6 (1.7) -0.7 (-2.1, 0.8) 0.34 
     
Insulin 30min incrementb 57.5 (46.1,92.2) 26.5 (21.5,39.5) 31.0 (8.4, 63.2) 0.01 
CPeptide 30min increment 2.8 (1.4) 2.1 (0.9) 0.7 (-0.3, 1.8) 0.16 
     
HDL 0.76 (0.05) 0.91 (0.10) -0.14 (-0.36, 0.08) 0.49 
Triglycerides 1.22 (0.11) 1.03 (0.14) 0.19 (-0.17, 0.56) 0.27 
ALT 21.9 (13.7) 18.9 (7.4) 3.1 (-6.8, 12.9) 0.77 
SBP 130.2 (13.5) 127.5 (14.5) 2.8 (-9.2, 14.7) 0.86 
     
Weight loss at 8 weeks     
Weight loss (Kg) 10.7 (5.3) 9.2 (3.8) 1.5 (-2.5, 5.5) 0.18 
% Change from baseline  10.1 (3.6) 9.4 (2.3) 0.7 (-2.0, 3.3) 0.32 
Category of weight loss     
<10Kg (%) 42.9 57.1   
>=10Kg (%) 81.8 18.2 1.9 (1.0, 3.7)c 0.048 
aRisk ratio: men vs women; bMedian values (IQR);  cRisk ratio >=10Kg vs < 10Kg 
  
Table 4 – Modelled early (Phib) and total (Phitot) insulin secretion during meal tests at 
baseline, 8 weeks and 8 months. Figures are means (SD) unless otherwise stated  
 
 Responders Non-responders Difference  
(95% CIs) 
p value 
Baseline     
Phib 0.89 (0.29) 0.68 (0.33) 0.21 (-0.19, 0.61) 0.27 
Phitot 77.1 (42.6) 47.1 (23.7) 30 (-17.3, 77.3) 0.19 
     
8 weeks     
Phib 1.18 (0.71) 0.47 (0.26) 0.71 (0.12, 1.31) 0.01 
Phitot 89.7 (49.9) 48.2 (27.1) 41.5 (-2.9, 85.9) 0.06 
     
8 months     
Phib 1.07 (0.61) 0.25 (0.13) 0.82 (0.44, 1.20) <0.001 
Phitot 98.6 (69.5) 37.4 (26.8) 61.2 (15.3, 107.1) 0.01 
. 
  
Figure 1 – Overview of the study design 
 
  
Figure 2  Change in response to the standard meal at baseline, after weight loss and after 
8 months follow up 
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